Overview

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Status:
Completed

Trial end date:
2020-05-22

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (HS).

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Antibodies, Monoclonal